161 related articles for article (PubMed ID: 11472210)
1. Disabling erbB receptors with rationally designed exocyclic mimetics of antibodies: structure-function analysis.
Berezov A; Zhang HT; Greene MI; Murali R
J Med Chem; 2001 Aug; 44(16):2565-74. PubMed ID: 11472210
[TBL] [Abstract][Full Text] [Related]
2. Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo.
Park BW; Zhang HT; Wu C; Berezov A; Zhang X; Dua R; Wang Q; Kao G; O'Rourke DM; Greene MI; Murali R
Nat Biotechnol; 2000 Feb; 18(2):194-8. PubMed ID: 10657127
[TBL] [Abstract][Full Text] [Related]
3. AHNP-streptavidin: a tetrameric bacterially produced antibody surrogate fusion protein against p185her2/neu.
Masuda K; Richter M; Song X; Berezov A; Masuda K; Murali R; Greene MI; Zhang H
Oncogene; 2006 Dec; 25(59):7740-6. PubMed ID: 16785990
[TBL] [Abstract][Full Text] [Related]
4. Polyethylene glycol-conjugated HER2-targeted peptides as a nuclear imaging probe for HER2-overexpressed gastric cancer detection in vivo.
Guan SS; Wu CT; Chiu CY; Luo TY; Wu JY; Liao TZ; Liu SH
J Transl Med; 2018 Jun; 16(1):168. PubMed ID: 29921305
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a novel nonphosphorylated pentapeptide motif displaying high affinity for Grb2-SH2 domain by the utilization of 3'-substituted tyrosine derivatives.
Song YL; Peach ML; Roller PP; Qiu S; Wang S; Long YQ
J Med Chem; 2006 Mar; 49(5):1585-96. PubMed ID: 16509576
[TBL] [Abstract][Full Text] [Related]
6. A designed cyclic peptide based on Trastuzumab used to construct peptide-drug conjugates for its HER2-targeting ability.
Zhou J; Zou Y; Cai Y; Chi F; Huang W; Shi W; Qian H
Bioorg Chem; 2021 Dec; 117():105453. PubMed ID: 34736138
[TBL] [Abstract][Full Text] [Related]
7. HER2-mediated internalization of a targeted prodrug cytotoxic conjugate is dependent on the valency of the targeting ligand.
Guillemard V; Nedev HN; Berezov A; Murali R; Saragovi HU
DNA Cell Biol; 2005 Jun; 24(6):350-8. PubMed ID: 15941387
[TBL] [Abstract][Full Text] [Related]
8. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
[TBL] [Abstract][Full Text] [Related]
9. 186Re-labeled antibodies to p185HER2 as HER2-targeted radioimmunopharmaceutical agents: comparison of physical and biological characteristics with 125I and 131I-labeled counterparts.
Kotts CE; Su FM; Leddy C; Dodd T; Scates S; Shalaby MR; Wirth CM; Giltinan D; Schroff RW; Fritzberg AR; Shepard HM; Slamon DJ; Hutchins BM
Cancer Biother Radiopharm; 1996 Apr; 11(2):133-44. PubMed ID: 10851530
[TBL] [Abstract][Full Text] [Related]
10. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.
Baselga J; Norton L; Albanell J; Kim YM; Mendelsohn J
Cancer Res; 1998 Jul; 58(13):2825-31. PubMed ID: 9661897
[TBL] [Abstract][Full Text] [Related]
11. Novel bioactive and stable neurotensin peptide analogues capable of delivering radiopharmaceuticals and molecular beacons to tumors.
Achilefu S; Srinivasan A; Schmidt MA; Jimenez HN; Bugaj JE; Erion JL
J Med Chem; 2003 Jul; 46(15):3403-11. PubMed ID: 12852770
[TBL] [Abstract][Full Text] [Related]
12. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
[TBL] [Abstract][Full Text] [Related]
14. Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth.
Sarup JC; Johnson RM; King KL; Fendly BM; Lipari MT; Napier MA; Ullrich A; Shepard HM
Growth Regul; 1991 Jun; 1(2):72-82. PubMed ID: 1688187
[TBL] [Abstract][Full Text] [Related]
15. Macrocyclization in the design of non-phosphorus-containing Grb2 SH2 domain-binding ligands.
Shi ZD; Wei CQ; Lee K; Liu H; Zhang M; Araki T; Roberts LR; Worthy KM; Fisher RJ; Neel BG; Kelley JA; Yang D; Burke TR
J Med Chem; 2004 Apr; 47(8):2166-9. PubMed ID: 15056012
[TBL] [Abstract][Full Text] [Related]
16. Anti-HER2/neu peptide producing vector system for biologic therapy - is it possible to mass-produce the peptide?
Park BW; Kim KS; Heo MK; Lee KS; Kim EK; Kim KS
Yonsei Med J; 2003 Feb; 44(1):58-64. PubMed ID: 12619176
[TBL] [Abstract][Full Text] [Related]
17. Conformation/activity studies of rationally designed potent anti-adhesive RGD peptides.
Gurrath M; Müller G; Kessler H; Aumailley M; Timpl R
Eur J Biochem; 1992 Dec; 210(3):911-21. PubMed ID: 1483474
[TBL] [Abstract][Full Text] [Related]
18. A structure-based approach to a synthetic vaccine for HIV-1.
Cabezas E; Wang M; Parren PW; Stanfield RL; Satterthwait AC
Biochemistry; 2000 Nov; 39(47):14377-91. PubMed ID: 11087390
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, solution structure, and biological evaluation of urokinase type plasminogen activator (uPA)-derived receptor binding domain mimetics.
Schmiedeberg N; Schmitt M; Rölz C; Truffault V; Sukopp M; Bürgle M; Wilhelm OG; Schmalix W; Magdolen V; Kessler H
J Med Chem; 2002 Nov; 45(23):4984-94. PubMed ID: 12408709
[TBL] [Abstract][Full Text] [Related]
20. Enzymatic conjugation using branched linkers for constructing homogeneous antibody-drug conjugates with high potency.
Anami Y; Xiong W; Gui X; Deng M; Zhang CC; Zhang N; An Z; Tsuchikama K
Org Biomol Chem; 2017 Jul; 15(26):5635-5642. PubMed ID: 28649690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
